

# Notice of Results and AGM

RNS Number : 99360

Novacyt S.A.

20 May 2024

NOVACYT

**Novacyt S.A.**

**("Novacyt", the "Company" or the "Group")**

## **Notice of Results and Annual General Meeting**

**Paris, France, and Eastleigh and Manchester, UK - 20 May 2024** - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it will report its audited financial results for the year ended 31 December 2023 on Thursday, 30 May 2024.

The Company also announces that its Annual General Meeting ("AGM") will be held at 2pm CEST/1pm BST on Wednesday, 26 June 2024 as an open virtual meeting. Further details of the AGM will be provided to shareholders in due course.

### **Investor webinar**

An investor webinar presentation by Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer, relating to the FY 2023 results will take place at 11.00am BST on Thursday, 30 May 2024.

The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation. Automated French subtitling will be available throughout the presentation.

Investors can sign up for the webinar via:

<https://www.investormeetcompany.com/novacyt-sa/register-investor>

Investors who already follow NOVACYT S.A. on the Investor Meet Company platform will automatically be invited.

## Contacts

<b>Novacyt SA</b>	<a href="https://novacyt.com/investors">https://novacyt.com/investors</a>
Lyn Rees, Chief Executive Officer	<b>Via Walbrook PR</b>
Steve Gibson, Chief Financial Officer	
<b>SP Angel Corporate Finance LLP (Nominated Adviser and Broker)</b>	+44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)	
<b>Deutsche Numis (Joint Broker)</b>	+44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Michael Palser	
<b>Allegra Finance (French Listing Sponsor)</b> Rémi Durgetto / Yannick Petit	+33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com
<b>Walbrook PR (Financial PR &amp; IR)</b> Stephanie Cuthbert / Paul McManus / Phillip Marriage / Alice Woodings	+44 (0)20 7933 8780 or novacyt@walbrookpr.com +44 (0)7796 794 663 / +44 (0)7980 541 893 +44 (0)7867 984 082 / +44 (0)7407 804 654

### About Novacyt Group ([www.novacyt.com](http://www.novacyt.com))

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

<b>Clinical</b>	<p>Broad portfolio of human clinical <i>in vitro</i> diagnostic products, workflows and services focused on three therapeutic areas:</p> <ul style="list-style-type: none"> <li>· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests</li> <li>· Precision Medicine: DPYD genotyping assay</li> <li>· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel</li> </ul>
<b>Instrumentation</b>	<p>Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:</p> <ul style="list-style-type: none"> <li>· Ranger® Technology: automated DNA sample preparation and target enrichment technology</li> <li>MyGo: real-time quantitative PCR (qPCR) instruments</li> </ul>
<b>Research Use Only</b>	<p>Range of services for the research industry:</p> <ul style="list-style-type: none"> <li>· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry</li> <li>· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)</li> </ul>

Novacyt is headquartered in Vélizy in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com). RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORGZGMKRNGGDZM